Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion

被引:26
作者
Cameron, Jamie [2 ]
Holla, Oystein L. [2 ]
Berge, Knut Erik [2 ]
Kulseth, Mari Ann [2 ]
Ranheim, Trine [2 ]
Leren, Trond P. [2 ]
Laerdahl, Jon K. [1 ]
机构
[1] Natl Hosp Norway, Univ Hosp, Inst Med Microbiol, CMBN, NO-0027 Oslo, Norway
[2] Natl Hosp Norway, Univ Hosp, Dept Med Genet, Med Genet Lab, NO-0027 Oslo, Norway
关键词
evolutionary conservation; LDL cholesterol; LDL receptor; PCSK9; structural bioinformatics;
D O I
10.1111/j.1742-4658.2008.06553.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Proprotein convertase subtilisin/kexin type 9 (PCSK9) interferes with the recycling of low-density lipoprotein (LDL) receptor (LDLR). This leads to LDLR degradation and reduced cellular uptake of plasma LDL. Naturally occurring human PCSK9 loss-of-function mutations are associated with low levels of plasma LDL cholesterol and a reduced risk of coronary heart disease. PCSK9 gain-of-function mutations result in lower LDL clearance and increased risk of atherosclerosis. The exact mechanism by which PCSK9 disrupts the normal recycling of LDLR remains to be determined. In this study, we have assembled homologs of human PCSK9 from 20 vertebrates, a cephalochordate and mollusks in order to search for conserved regions of PCSK9 that may be important for the PCSK9-mediated degradation of LDLR. We found a large, conserved protrusion on the surface of the PCSK9 catalytic domain and have performed site-directed mutagenesis experiments for 13 residues on this protrusion. A cluster of residues that is important for the degradation of LDLR by PCSK9 was identified. Another cluster of residues, at the opposite end of the conserved protrusion, appears to be involved in the physical interaction with a putative inhibitor of PCSK9. This study identifies the residues, sequence segments and surface patches of PCSK9 that are under strong purifying selection and provides important information for future studies of PCSK9 mutants and for investigations on the function of this regulator of cholesterol homeostasis.
引用
收藏
页码:4121 / 4133
页数:13
相关论文
共 39 条
[1]
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].
Abifadel, M ;
Varret, M ;
Rabès, JP ;
Allard, D ;
Ouguerram, K ;
Devillers, M ;
Cruaud, C ;
Benjannet, S ;
Wickham, L ;
Erlich, D ;
Derré, A ;
Villéger, L ;
Farnier, M ;
Beucler, I ;
Bruckert, E ;
Chambaz, J ;
Chanu, B ;
Lecerf, JM ;
Luc, G ;
Moulin, P ;
Weissenbach, J ;
Prat, A ;
Krempf, M ;
Junien, C ;
Seidah, NG ;
Boileau, C .
NATURE GENETICS, 2003, 34 (02) :154-156
[2]
Allard Delphine, 2005, Hum Mutat, V26, P497, DOI 10.1002/humu.9383
[3]
The universal protein resource (UniProt) [J].
Bairoch, Amos ;
Bougueleret, Lydie ;
Altairac, Severine ;
Amendolia, Valeria ;
Auchincloss, Andrea ;
Puy, Ghislaine Argoud ;
Axelsen, Kristian ;
Baratin, Delphine ;
Blatter, Marie-Claude ;
Boeckmann, Brigitte ;
Bollondi, Laurent ;
Boutet, Emmanuel ;
Quintaje, Silvia Braconi ;
Breuza, Lionel ;
Bridge, Alan ;
deCastro, Edouard ;
Coral, Danielle ;
Coudert, Elisabeth ;
Cusin, Isabelle ;
Dobrokhotov, Pavel ;
Dornevil, Dolnide ;
Duvaud, Severine ;
Estreicher, Anne ;
Famiglietti, Livia ;
Feuermann, Marc ;
Gehant, Sebastian ;
Farriol-Mathis, Nathalie ;
Ferro, Serenella ;
Gasteiger, Elisabeth ;
Gateau, Alain ;
Gerritsen, Vivienne ;
Gos, Arnaud ;
Gruaz-Gumowski, Nadine ;
Hinz, Ursula ;
Hulo, Chantal ;
Hulo, Nicolas ;
Ioannidis, Vassilios ;
Ivanyi, Ivan ;
James, Janet ;
Jain, Eric ;
Jimenez, Silvia ;
Jungo, Florence ;
Junker, Vivien ;
Keller, Guillaume ;
Lachaize, Corinne ;
Lane-Guermonprez, Lydie ;
Langendijk-Genevaux, Petra ;
Lara, Vicente ;
Lemercier, Philippe ;
Le Saux, Virginie .
NUCLEIC ACIDS RESEARCH, 2007, 35 :D193-D197
[4]
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol [J].
Benjannet, S ;
Rhainds, D ;
Essalmani, R ;
Mayne, J ;
Wickham, L ;
Jin, WJ ;
Asselin, MC ;
Hamelin, J ;
Varret, M ;
Allard, D ;
Trillard, M ;
Abifadel, M ;
Tebon, A ;
Attie, AD ;
Rader, DJ ;
Boileau, C ;
Brissette, L ;
Chrétien, M ;
Prat, A ;
Seidah, NG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48865-48875
[5]
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications [J].
Benjannet, Suzanne ;
Rhainds, David ;
Hamelin, Josee ;
Nassoury, Nasha ;
Seidah, Nabil G. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (41) :30561-30572
[6]
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy [J].
Berge, KE ;
Ose, L ;
Leren, TP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) :1094-1100
[7]
Characterization of novel mutations in the catalytic domain of the PCSK9 gene [J].
Cameron, J. ;
Holla, O. L. ;
Laerdahl, J. K. ;
Kulseth, M. A. ;
Ranheim, T. ;
Rognes, T. ;
Berge, K. E. ;
Leren, T. P. .
JOURNAL OF INTERNAL MEDICINE, 2008, 263 (04) :420-431
[8]
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors [J].
Cameron, J ;
Holla, OL ;
Ranheim, T ;
Kulseth, MA ;
Berge, KE ;
Leren, TP .
HUMAN MOLECULAR GENETICS, 2006, 15 (09) :1551-1558
[9]
The Jalview Java']Java alignment editor [J].
Clamp, M ;
Cuff, J ;
Searle, SM ;
Barton, GJ .
BIOINFORMATICS, 2004, 20 (03) :426-427
[10]
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].
Cohen, JC ;
Boerwinkle, E ;
Mosley, TH ;
Hobbs, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272